Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

2 Equal-Weighted ETFs For Potentially Better Performance

By Investing.com (Tezcan Gecgil/Investing.com )ETFsMay 21, 2021 23:33
au.investing.com/analysis/2-equalweighted-etfs-for-potentially-better-performance-200467928
2 Equal-Weighted ETFs For Potentially Better Performance
By Investing.com (Tezcan Gecgil/Investing.com )   |  May 21, 2021 23:33
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Equal-weighted exchange-traded funds (ETFs) invest equal amounts in businesses irrespective of their market capitalizations. Conversely, a cap-weighted index, allows companies with larger market caps to have a significant impact on the index value. In recent decades, capitalization-weighted indexing has become the dominant methodology.

For example, the S&P 500 is a market-cap-weighted index, and the SPDR® S&P 500 (NYSE:SPY) gives access to this index. Apple (NASDAQ:AAPL), whose market cap is $2.08 trillion, has the highest weighting (5.65%) in SPY, followed by Microsoft (NASDAQ:MSFT) and Amazon (NASDAQ:AMZN). The top 10 stocks comprise about 28% of the fund.

Recent research led by Bernd Hanke of Global Systematic Investors and Aneel Keswani Cass Business School in London, concludes that equal-weighted funds offer greater diversification and typically perform better.

Against that background, here are two equally-weighted ETFs that could appeal to investors who do not want to buy top-heavy funds concentrated in a handful of stocks.

1. Invesco S&P 500 Equal Weight ETF

Current Price: $149.15
52-Week Range: $94.86 - $152.85
Dividend Yield: 1.36%
Expense Ratio: 0.20% per year

The Invesco S&P 500® Equal Weight ETF (NYSE:RSP) is an equal-weighted version of SPY. Since its inception in April 2003, net assets have reached $27.8 billion.

RSP Weekly
RSP Weekly

RSP tracks the S&P 500 Equal Weighted Index, which equally weights the stocks in the S&P 500 Index. Both the index and the fund are rebalanced quarterly.

The top 10 stocks comprise close to 2.5% of the fund. Among the leading names are the steelmaker Nucor (NYSE:NUE), railroad and line-haul operator Kansas City Southern (NYSE:KSU), consumer credit reporting agency Equifax (NYSE:EFX), electronic data storage group Seagate Technology (NASDAQ:STX) and package delivery giant United Parcel Service (NYSE:UPS). The giant tech companies, including Apple, MSFT and AMZN, each have a weighting of 0.20%.

In the past 12 months, RSP is up almost 56% and has returned 16.1% year-to-date (YTD). By comparison, SPY is up 40.8% in the past year and 9.9% YTD. Put another way, the size factor has meant that RSP has outperformed SPY in recent months. Both ETFs hit all-time highs in early May.

We believe the fund could be appropriate for most long-term portfolios. Its forward P/E and P/B ratios stand at 20.76 and 3, respectively. A potential decline toward $145 or below would offer better value.

2. SPDR S&P Biotech ETF

Current Price: $127.57
52-Week Range: $97.15 - $174.79
Dividend Yield: 0.26%
Expense Ratio: 0.35% per year

This fund comes from the health space. The SPDR® S&P Biotech ETF (NYSE:XBI) invests in 170 biotechnology stocks. The fund started trading in January 2006, and net assets stand at $6.8 billion.

XBI Weekly
XBI Weekly

XBI tracks the S&P Biotechnology Select Industry, which is equal-weighted. Around 9.5% of the fund is in the top 10 companies, whose market caps range from $1.1 billion to $63.5 billion.

Among the top names in its roster: Curis (NASDAQ:CRIS), which concentrates on cancer treatments; United Therapeutics (NASDAQ:UTHR), which focuses is on treatment of chronic and life-threatening conditions; biopharma group Alexion Pharmaceuticals (NASDAQ:ALXN); Moderna (NASDAQ:MRNA), which has developed one of the leading vaccines against COVID-19; and Humanigen (NASDAQ:HGEN), which focuses on rare diseases.

Most analysts concur that the biotechnology sector is innovative. The rush to develop vaccines and treatments for the pandemic is a testament to the growth potential of the industry. In the past 12 months, XBI returned more than 21% and hit an all-time high on Feb. 9. However, YTD, the fund is down 11.2%. We like the diversity of the fund. Potential investors could consider investing in XBI around these levels.

On a final note, by comparison, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), which is a cap-weighted fund, has returned 11% in the past 12 months, but is down almost 2% YTD. It is another widely-followed ETF with close to $10 billion under management.

2 Equal-Weighted ETFs For Potentially Better Performance
 

Related Articles

2 Equal-Weighted ETFs For Potentially Better Performance

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email